Pharmasset (VRUS +10.7%) jumps after announcing earlier it's initiated Phase 3 studies for its...

|By:, SA News Editor

Pharmasset (VRUS +10.7%) jumps after announcing earlier it's initiated Phase 3 studies for its hepatitis C virus nucleotide analog, PSI-7977.